Form 8-K · Current report
News Corp 8-K, filed Oct 15, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000222
Summary
News Corp repurchased 58,482 Class A common shares on 14 October 2026 for about US$1.71 million, bringing cumulative Class A buy-backs to 13,220,710 shares for roughly US$348.2 million. The company said it has purchased approximately US$532.9 million of Class A and Class B shares in total under its US$1 billion 2025 repurchase program.
Key points
- News Corp is authorized to buy back up to US$1 billion of its Nasdaq-listed Class A and Class B common stock under a program authorized as of 15 July 2025.
- Cumulative buy-backs reported to the ASX stand at 13,220,710 Class A shares for total consideration of about US$348.2 million.
- Highest price paid for Class A shares under the program was US$31.58 on 27 August 2026 and the lowest was US$22.20 on 9 February 2026.
- No ASX-listed CDIs will be repurchased under the program, and the buy-back is intended to enhance shareholder value.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.